Significant Scientific Agreement Standard Could Be Revised Under McClellan

FDA may revisit its significant scientific agreement standard for health claims, Commissioner Mark McClellan, MD/PhD, said at an American Enterprise Institute conference in Washington, D.C. Dec. 11